American patients

影響を受けたインシデント

インシデント 1723 Report
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

2020-07-01

NarxCare's overdose risk algorithm, lacking peer-reviewed validation, uses sensitive data like doctor visits, prescriptions, and possibly genetic information, leading to significant biases against women and Black patients. Factors like sexual abuse and criminal records exacerbate stigmas and disparities, often resulting in unjust denial of necessary pain medication. The newly approved AvertD genetic test shares similar issues, further complicating and potentially harming medical treatment decisions.

Related Entities

Appriss

開発者と提供者の両方の立場で関わったインシデント

インシデント 172
3 レポート
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

NarxCare

Incidents involved as Deployer

インシデント 172
3 レポート
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

AvertD

Incidents involved as Deployer

インシデント 172
3 レポート
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

American physicians

影響を受けたインシデント

インシデント 172
3 レポート
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

American pharmacists

影響を受けたインシデント

インシデント 172
3 レポート
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias

American patients of minority groups

影響を受けたインシデント

インシデント 172
3 レポート
NarxCare’s Risk Score Model Allegedly Lacked Validation and Trained on Data with High Risk of Bias